$0M
Ecosystem Market Cap
$0.0M+
Research Funded
0+
Projects Launched
0K+
Community Members
Trusted by frontier DeSci Projects
“A growing number of scientists and entrepreneurs are leveraging blockchain tools, in an attempt to improve modern science. Collectively, their work has become known as the decentralized science movement, or DeSci.”
dbcrypto
Featured Labs
An open global community collectively sourcing and nurturing solutions to advance brain health and prevent neurodegeneration with a focus on tackling Alzheimer's first.
7
Projects Funded
$947.79K
Funding Deployed
Top Project
Transfidelity for Protein Stability
Neurodegenerative diseases such as Alzheimer's Disease are devastating conditions that impact millions globally. These diseases are driven by the misfolding and aggregation of proteins, which lead to brain cell death and cognitive decline. To make matters worse, as we age our cells become more error-prone, resulting in more errors during protein printing, causing proteins to clump together and form aggregates. Project Transfidelity aims to solve this by improving the accuracy of protein printing, preventing toxic aggregates from forming. Led by Dr. Dimitri Scherbakov and Dr. Rashid Akbergenov, with over 50 years of combined experience in the lab, we have identified two molecules that may improve the efficiency of protein production, potentially preventing protein aggregates, hypothesized to cause dementia. Despite the significant research funding allocated to neurodegenerative diseases, current therapies continue to treat the symptoms caused by the protein aggregates, with little progress made to stop or reverse disease. We’re trying to go after a potential root cause - rather than trying to clear aggregates once they are there, we aim to prevent them from forming in the first place by reducing the production of faulty proteins. With a clear path towards developing novel intellectual property (IP) and an ever-growing target market, we believe we are poised to make an impact on neurodegenerative disorders and the way we age.
VitaDAO's mission is to extend human healthspan and lifespan through accelerated research, open collaboration, and innovative funding structures that align incentives across the longevity ecosystem.
17
Projects Funded
$2.87M
Funding Deployed
Top Project
The Longevity Molecule
The study, consisting of over 1.4 billion prescriptions, found that a number of prescription drugs were highly associated with longer life- and health-span in long-live populations. Here, we present a unique investment opportunity. We seek to validate these observations through a series of carefully conducted wet lab experiments. If successful, this work could result in the repurposing of several FDA-approved therapeutics for the purpose of extending human lifespan, at a lower cost and over faster timelines than conceivably possible with de novo drug discovery. This unique investment opportunity allows savvy longevity investors the chance to own a share of the potential intellectual property generated from these studies, and in turn, a potential share in the future of life extension. Aims, Hypothesis & Results The global elderly population is projected to substantially increase throughout the 21st century. By the year 2100 a fifth of the total world population will be aged 65 or older, posing a serious socioeconomic challenge to societies world-wide. Interventions that ensure healthy aging are therefore of critical importance. Timeline The Scheibye-Knudsen Lab will test the identified drugs' ability to attenuate features of aging in a controlled laboratory setting. Here, the molecules will be tested in human cells and in the animal model drosophila melanogaster (fruit flies). Fruit flies are used extensively in biomedical research and particular aging research as they have a short lifespan of about 60 days. Additionally, the drugs will be tested in human cells to rapidly understand how the molecules affect human cellular aging.
